Literature DB >> 11375796

The effects of long-term metformin treatment on adrenal and ovarian steroidogenesis in women with polycystic ovary syndrome.

J Vrbíková1, M Hill, L Stárka, D Cibula, B Bendlová, K Vondra, J Sulcová, M Snajderová.   

Abstract

OBJECTIVE: To evaluate adrenal and ovarian steroidogenesis before and after long-term treatment with metformin in women with polycystic ovary syndrome (PCOS). DESIGN AND METHODS: Twenty-four women with PCOS were evaluated before and after treatment (27+/-4 weeks) with metformin (1000 mg/day) using adrenocorticotrophin (ACTH), GnRH analogue and oral glucose tolerance (oGTT) tests. For statistical evaluation, ANOVA and Wilcoxon's test were used.
RESULTS: In 58% of the women a significant improvement in menstrual cyclicity was observed. No significant change in basal steroid levels was found. After ACTH stimulation, a significant decrease in the activity of 3 beta-hydroxysteroid dehydrogenase in C(21) steroids (P<0.05) and in 17 beta-hydroxysteroid dehydrogenase (P<0.01) was observed, as was an increase in the activity of C17,20-lyase in the Delta(4) pathway (P<0.01). A significant growth in the dehydroepiandrosterone (DHEA)/DHEA-sulfate ratio (P<0.05) was detected. With regard to ovarian steroidogenesis, a significant decrease in the stimulated levels of testosterone (P<0.05), index of free testosterone (P<0.01), LH (P<0.05) and oestradiol (P<0.01), and an increase in the levels of 17-hydroxypregnenolone (P<0.05) were detected. In the indices of ovarian enzyme activities, we observed a significant decrease in 3 beta-hydroxysteroid dehydrogenase in C21 steroids (P<0.01), in C17,20-lyase in the Delta 5 pathway (P<0.01), in 17 beta-hydroxysteroid dehydrogenase (P<0.05) and in aromatase. In glucose metabolism, a tendency towards reduction in the homeostasis model assessment (HOMA)-R (for insulin resistance) and HOMA-F (for beta cell function) was detected. In addition, an increase in the levels of C peptide during oGTT was observed (P<0.01).
CONCLUSIONS: Long-term metformin treatment reduced various steroid enzymatic activities both in the ovary and the adrenal glands, without apparent changes in basal steroid levels and in insulin sensitivity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11375796     DOI: 10.1530/eje.0.1440619

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  11 in total

1.  The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial.

Authors:  Trevor J Orchard; Marinella Temprosa; Ronald Goldberg; Steven Haffner; Robert Ratner; Santica Marcovina; Sarah Fowler
Journal:  Ann Intern Med       Date:  2005-04-19       Impact factor: 25.391

2.  Effect of Long-Term Metformin and Lifestyle in the Diabetes Prevention Program and Its Outcome Study on Coronary Artery Calcium.

Authors:  Ronald B Goldberg; Vanita R Aroda; David A Bluemke; Elizabeth Barrett-Connor; Matthew Budoff; Jill P Crandall; Dana Dabelea; Edward S Horton; Kieren J Mather; Trevor J Orchard; David Schade; Karol Watson; Marinella Temprosa
Journal:  Circulation       Date:  2017-05-05       Impact factor: 29.690

3.  Effect of metformin and flutamide on insulin, lipogenic and androgen-estrogen signaling, and cardiometabolic risk in a PCOS-prone metabolic syndrome rodent model.

Authors:  M Kupreeva; A Diane; R Lehner; R Watts; M Ghosh; S Proctor; D Vine
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-08-28       Impact factor: 4.310

4.  Metformin attenuates steroidogenesis in ovarian follicles of the broiler breeder hen.

Authors:  Evelyn A Weaver; Ramesh Ramachandran
Journal:  Reproduction       Date:  2020-11       Impact factor: 3.906

5.  The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial.

Authors:  V Soldat-Stanković; S Popović-Pejičić; S Stanković; A Prtina; G Malešević; J Bjekić-Macut; S Livadas; S Ognjanović; G Mastorakos; D Micić; D Macut
Journal:  J Endocrinol Invest       Date:  2021-10-19       Impact factor: 4.256

6.  In polycystic ovary syndrome, adrenal steroids are regulated differently in the morning versus in response to nutrient intake.

Authors:  Dumindra Gurusinghe; Sharan Gill; Rogelio U Almario; Jennifer Lee; William F Horn; Nancy L Keim; Kyoungmi Kim; Sidika E Karakas
Journal:  Fertil Steril       Date:  2009-04-01       Impact factor: 7.329

7.  State of the Art Review: Emerging Therapies: The Use of Insulin Sensitizers in the Treatment of Adolescents with Polycystic Ovary Syndrome (PCOS).

Authors:  David H Geller; Danièle Pacaud; Catherine M Gordon; Madhusmita Misra
Journal:  Int J Pediatr Endocrinol       Date:  2011-08-26

8.  Diamel therapy in polycystic ovary syndrome reduces hyperinsulinaemia, insulin resistance, and hyperandrogenaemia.

Authors:  Arturo Hernández-Yero; Felipe Santana Pérez; Gisel Ovies Carballo; Eduardo Cabrera-Rode
Journal:  Int J Endocrinol       Date:  2012-06-21       Impact factor: 3.257

9.  Metformin inhibits aromatase via an extracellular signal-regulated kinase-mediated pathway.

Authors:  Suman Rice; Laura Pellatt; Kumaran Ramanathan; Saffron Anne Whitehead; Helen Diane Mason
Journal:  Endocrinology       Date:  2009-07-02       Impact factor: 4.736

10.  Adrenocortical production is associated with higher levels of luteinizing hormone in nonobese women with polycystic ovary syndrome.

Authors:  Luciana Tock; Gláucia Carneiro; Andrea Z Pereira; Sérgio Tufik; Maria Teresa Zanella
Journal:  Int J Endocrinol       Date:  2014-05-07       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.